PRESS RELEASE DUBLIN, Feb. 18, 2015 /PRNewswire/ –Actavis plc today announced that it will adopt a fresh corporate name – Allergan – following anticipated effective completion of the acquisition of Allergan, Inc.The Company said that it intends to use the Allergan name as its corporate name and for its global branded pharmaceutical portfolio, and will retain the Actavis name for select geographic regions and product portfolios. The transformation in corporate name would be at the mercy of approval by Actavis' shareholders at its Annual General Interacting with later this year. ‘The pending combination of Actavis and Allergan will generate a dynamic new breed of company – a head in Development Pharma.These two applications are synergistic and offer complementary services to the same communities often,’ the blog notes . This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health Information, an independent news service editorially, is an application of the Kaiser Family Foundation, a nonpartisan healthcare policy research business unaffiliated with Kaiser Permanente.. AARDA releases white colored paper to educate its members, individual community about biosimilar medicines The American Autoimmune Related Diseases Association , a national nonprofit health organization focused on increasing knowing of autoimmune diseases, today issued a white paper to teach its membership and the individual community about biosimilar medicines after a survey found most patients were generally unacquainted with this new category of medicines which might soon be approved in the U.S.